Status:
UNKNOWN
Molecular Basis of Loss Aversion
Lead Sponsor:
Sir Run Run Shaw Hospital
Conditions:
Healthy
Eligibility:
All Genders
25-40 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to test the roles of dopamine and norepinephrine in decision making related to loss aversion in the healthy population. The main question it aims to answer is whethe...
Eligibility Criteria
Inclusion
- Age 25-40 years old (including boundary value).
- Elementary school education or above, able to understand the research content.
- Body temperature, blood pressure, heart rate, respiratory rate, and electrocardiogram are all normal. Among them, the blood pressure range is 100-139/70-89 mmHg, and the heart rate range is 60-85 beats/min.
Exclusion
- Vulnerable groups, including people with mental illness, cognitive impairment, critically ill subjects, minors, pregnant women, illiterates, etc.
- Family history of genetic diseases.
- Major physical diseases, including cardiovascular, respiratory, digestive, renal, endocrine, blood and other systemic diseases.
- History of alcohol/drug dependence.
- Lactating women.
- The cardiopulmonary function test results are poor.
- Have ever taken madopar or propranolol for medical use.
Key Trial Info
Start Date :
September 18 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06034158
Start Date
September 18 2023
End Date
September 1 2024
Last Update
September 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China, 360000